List

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for the given year is not complete until April of the following year. Annual Reports data is a snapshot of agency reported information for that year and hence might look different from the live data in the Awards Information charts.

Displaying 169241 - 169250 of 173101 results
  1. Regulatory Validation of Standardized Clinical Immunohistochemistry Controls

    SBC: MEDICAL DISCOVERY PARTNERS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): The broad, long-term goal of this project is consistent, standardized diagnostic testing of surgical biopsies by immunohistochemistry (IHC). The methods to achieve this goal are well understood in the field of clinicallaboratory testing: (1) standardization of reagents and protocols, (2) automation to reduce human errors, and (3) the use of standardized control ...

    SBIR Phase I 2014 Department of Health and Human Services
  2. A NOVEL TARGETED DELIVERY SYSTEM FOR CANCER TREATMENT AND DIAGNOSIS

    SBC: EnduRx Pharmaceuticals Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): Glioblastoma multiforme (GBM) or glioblastoma, is the most common and aggressive malignant primary brain tumor in humans. An effective treatment that increases patient survival would represent a significant advance inthe field, and provide a desperately needed new therapy for this deadly disease. EnduRx is focused on the development of new, targeted systems f ...

    SBIR Phase I 2014 Department of Health and Human Services
  3. A Phase I trial combining IV fenretinide and IV safingol to target overproduction

    SBC: CERRX, INC.            Topic: NCI

    PROJECT SUMMARY/ABSTRACT CerRx, Inc., Lubbock TX, a clinical stage anticancer drug development start-up company, requests critical funding via this SBIR Fast-Track Phase I/II application to support a highly novel, adult Phase I clinical trial of intravenous fenretinide + safingol, for which it licenses both formulation and drug combination IP rights. This trial will be subcontracted to the academi ...

    SBIR Phase I 2014 Department of Health and Human Services
  4. Optically Actuated Needles for Oncological Applications

    SBC: INTELLIGENT FIBER OPTIC SYSTEMS CORPORATION            Topic: NCI

    DESCRIPTION (provided by applicant): In this FastTrack Phase I/II SBIR application, IFOS, in collaboration with the Stanford Center for Design Research (CDR) proposes to develop and validate an actively steered, photo-actuated, small-caliber needle for precise imaging-assisted percutaneous procedures. This innovation specifically addresses the need for precise needle placement in procedures target ...

    SBIR Phase I 2014 Department of Health and Human Services
  5. Liquid Helium Bath Free, Conduction Cooled Nb3Sn Superconducting 7 Tesla Plus Mag

    SBC: HYPER TECH RESEARCH, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): For 7 tesla full body MRI bore magnet systems, NbTi superconductor wire has reached its limit at 4 K. Above 7T if NbTi is used it requires super cooling of helium to 1.8-2.4 K to achieve 7-11T bore MRI and NMR systems.All these 7T full body MRI background magnets sold by Siemens, Philips, and GE have been manufactured by Aligent (formerly known at Varian before ...

    SBIR Phase I 2014 Department of Health and Human Services
  6. Lu-Free Scintillators for PET

    SBC: Radiation Monitoring Devices, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): Positron Emission Tomography (PET) is a functional imaging technique with the potential to quantify the rates of biological processes in vivo. PET imaging can provide diagnosis for symptoms of diseases such as cancer, Alzheimer's disease, head trauma, and stroke. However, to allow exploitation of the full potential of PET, there is urgent need for both imp ...

    SBIR Phase I 2014 Department of Health and Human Services
  7. BREATHE FREE: Smartphone Videogame-Based Incentives for Smoking Cessation

    SBC: ENTERTAINMENT SCIENCE PLAYMATICS, JV            Topic: NIDA

    DESCRIPTION (provided by applicant): Cigarette smoking remains the number one cause of preventable morbidity and mortality in the U.S. Each year, one third to one half of smokers attempt to quit at least once; however, approximately 94% of quit attempts fail. A number of interventions have been developed to help smokers initiate and maintain abstinence. Unfortunately, even though most smokers expr ...

    SBIR Phase I 2014 Department of Health and Human Services
  8. Bio-Activated Opioid Drugs with Unprecedented Oral and Non-Oral Abuse-Resistance

    SBC: ELYSIUM THERAPEUTICS, INC            Topic: NIDA

    DESCRIPTION: The abuse of prescription drugs is the fastest-growing drug problem in the United States, and reducing such abuse is a national priority. While one of the most prevalent routes of abuse for opioid medicines is the oral route, current formulation- and molecular-based technologies are primarily designed to resist abuse via non-oral routes (e.g., inhalation and injection). Consequently, ...

    SBIR Phase I 2014 Department of Health and Human Services
  9. Unprecedented Diversion-/Abuse-Resistance: Molecular Deactivation of Opioid Drugs

    SBC: ELYSIUM THERAPEUTICS, INC            Topic: NIDA

    DESCRIPTION: Elysium has discovered a novel molecular deactivation (XpiRx or expiring pill ) technology that is designed to effectively curb the widespread abuse and diversion of unused prescription opioid drugs. Using Elysium's technology, opioid drug products will safely, and irreversibly lose their potency over a specified time window beyond the prescribed use period, rendering them devo ...

    SBIR Phase I 2014 Department of Health and Human Services
  10. A proposal to develop a self-regulating hydromorphone tablet to deter excess oral

    SBC: ACURA PHARMACEUTICALS, INC.            Topic: NIDA

    DESCRIPTION: The medical misuse and non-medical use of prescription opioid analgesics is a significant problem in USA and its societal effects and cost have been well documented. The emergence of abuse deterrent opioid products into the marketplace is targeted to stem the advance of this complex problem. Although new abuse deterrent opioid products have been introduced which deter manipulation of ...

    SBIR Phase I 2014 Department of Health and Human Services

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government